The analysis of cancerous specimens collected from patients with stage II colon cancer (CRC) revealed that an elevated expression of SCD1 together with other three genes involved in lipid metabolism (ABCA1, ACSL1, AGPAT1) delineate a high-risk group of patients, characterized by a worse clinical outcome [139]. This evidence concerns the gene SCD and colonic neoplasm.